strong>Astrazeneca plc, of London, said the FDA approved Iressa (gefitinib) tablets, 250 mg once daily, for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.